Maxim Group analyst Jason Kolbert lifted his price target on Buy-rated Gilead Sciences (NASDAQ: GILD) from $89 to $98 heading ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE